This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

Study of Infigratinib in Children With Achondroplasia

  • Home•
  • Pages•
  • Study of Infigratinib in Children With Achondroplasia

6th March 2020

The Propel study aims to learn more about the overall health, growth, and possible medical complications in children with achondroplasia.

200 boys and girls are still being recruited to participate in the study at locations worldwide. No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for the Study of Infigratinib in Children With Achondroplasia - Propel 2.

PROPEL 2 is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study for at least 6 months. The study includes dose escalation with extended treatment and dose expansion.

QED study
Image credits: clinicaltrials.gov


The safety and efficacy of infigratinib have not been established and there is no guarantee that infigratinib will receive health authority approval or become commercially available in any country for the uses being investigated.

To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.